Now the drug is in clinical trials for IDH2 mutant-positive AML. How to Use:In vitro: AG-221 was used at 1 µM in vitro and cellular assays. In vivo: AG-221 was dosed orally to mice bearing IDH2 mutant tumors at 5-50 mg/Kg once per day. Reference: 1. http://investor.agios...